Objective-Aortic valve stenosis (AS) is characterized by fibrosis and calcification of valves leading to aortic valve narrowing, resulting in high wall shear stress across the valves. We previously demonstrated that high shear stress can activate platelet-derived transforming growth factor-β1 (TGF-β1), a cytokine that induces fibrosis and calcification. The aim of this study was to investigate the role of shear-induced platelet release of TGF-β1 and its activation in AS. Approach and Results-We studied hypercholesterolemic Ldlr +/+ (Reversa) mice that develop AS on Western diet and a surgical ascending aortic constriction mouse model that acutely simulates the hemodynamics of AS to study shear-induced platelet TGF-β1 release and activation. Reversa mice on Western diet for 6 months had thickening of the aortic valves, increased wall shear stress, and increased plasma TGF-β1 levels. There were weak and moderate correlations between wall shear stress and TGF-β1 levels in the progression and reversed Reversa groups and a stronger correlation in the ascending aortic constriction model in wild-type mice but not in mice with a targeted deletion of megakaryocyte and platelet TGF-β1 (Tgfb1 flox ). Plasma total TGF-β1 levels correlated with collagen deposition in the stenotic valves in Reversa mice. Although active TGF-β1 levels were too low to be measured directly, we found (1) canonical TGF-β1 (phosphorylated small mothers against decapentaplegic 2/3) signaling in the leukocytes and canonical and noncanonical (phosphorylated extracellular signal-regulated kinases 1/2) TGF-β1 signaling in aortic valves of Reversa mice on a Western diet, and (2) TGF-β1 signaling of both pathways in the ascending aortic constriction stenotic area in wild-type but not 
A ortic valve stenosis (AS) is a chronic disorder involving fibrosis and calcification of the aortic valve (AV).
1,2 The narrowing of the aortic orifice ultimately leads to congestive heart failure and sudden cardiac death. 3 Although there are common features between atherosclerotic coronary artery disease and AS, medical therapies for atherosclerosis have not been shown to prevent the progression of AS. The differences in rheology of the AV and coronary arteries may provide at least a partial explanation for the differences in pathophysiology and response to therapy. [4] [5] [6] [7] [8] AV has pulsatile shear stress on the ventricular side and low and reciprocating shear stress on the aortic side, 9 whereas the coronary artery is exposed to sustained laminar blood flow under normal circumstances. 10 As the stenosis progresses, wall shear stress (WSS) across the AV dramatically increases. 4 We previously demonstrated that in vitro shear stress can activate latent transforming growth factor-β1 (TGF-β1), 11 a critical profibrotic growth factor that can induce fibrosis and calcification. 12 We also showed that active TGF-β1 could be eluted from thrombi formed in response to vascular injury in the carotid artery of mice where partial occlusion may have led to high local shear stress. 11 Subsequently, Albro et al 13 independently confirmed that shear stress can activate latent TGF-β1 in synovial fluid. We recently reported that mice with targeted deletion of TGF-β1 in their megakaryocytes and platelets are partially protected from developing cardiac hypertrophy, fibrosis, and systolic dysfunction in response to constriction of the transverse aorta, a model that has increased WSS at the stenosis created and in the innominate artery. 14 Collectively, these data raise the possibility of an association between the activation of circulating latent TGF-β1 under high shear stress and the development of AS. Because platelets contribute ≈45% of the baseline circulating TGF-β1 level 14 and have 40× to 100× more latent TGF-β1 than any other cells, 15 it is possible that shear stress has 2 separate effects, namely, inducing release of latent TGF-β1 from platelets and activating the released latent TGF-β1. This mechanism may contribute to the progression of AS because AV narrowing increases shear stress, resulting in greater release of platelet TGF-β1 and TGF-β1 activation, which in turn may lead to progressive valve narrowing and fibrosis and thus even greater shear stress.
To test our hypothesis, we studied plasma TGF-β1 levels longitudinally in Ldlr +/+ mice (Reversa mice) that develop both severe hypercholesterolemia and AS on a Western diet (WD). [16] [17] [18] To further test the role of platelet-derived TGF-β1 release under high shear stress, we compared the responses of wild-type (WT) mice and mice with a targeted deletion in megakaryocyte and platelet TGF-β1 (Tgfb1   flox   ) to acute surgical constriction of the ascending aorta. This model more closely simulates the hemodynamics of advanced human AS than the transverse aortic constriction model that we previously studied because the stenosis is proximal to the innominate artery. To complement these in vivo models, we also assessed in vitro the response of human AV cells to TGF-β1 and the effect of platelet-derived TGF-β1 on leukocyte phosphorylation of the protein small mothers against decapentaplegic 2/3 (Smad2/3), an indicator of active TGF-β1 signaling in the circulation.
Material and Methods
Materials and Methods are available in the online-only Supplement.
Diet-Induced AV Stenosis
A total of 74 Reversa mice (8-12 weeks of age) were placed on either a chow diet or a WD (TD 88137; Harlan Teklad) and divided into the groups illustrated in the online-only Data Supplement Figure I: (1) progression group: 28 mice on a WD for ≤12 months; (2) reversed group: 27 mice fed a WD for 6 months that then received 4 injections of polyinosinic-polycytidylic acid (pI-pC, 225 μg, IP) at 2-day intervals to inactivate the Mttp gene and switched to a chow diet for another 6 months; and (3) control group: 19 Reversa mice maintained on a chow diet for 12 months and treated with pI-pC at the age of 6 weeks. Figure 1 . Mice in the progression group have higher wall shear stress (WSS) and increased plasma transforming growth factor-β1 (TGF-β1) levels. A, Aortic valve (AV) cusp separation distance in the 3 groups. B, WSS across the AV in the 3 groups. C, Transvalvular peak velocity in the 3 groups. D, Plasma total TGF-β1 levels of mice in the 3 groups. E and F, Correlation between the changes in TGF-β1 levels and WSS from baseline to 6 months (E) and from 9 to 12 months (F) in the 3 groups. For A and B, *P<0.01 compared with control group at the same time point and #P<0.01 compared with the group's own baseline value. The experimental design is shown in Figure I in the onlineonly Data Supplement. The cholesterol levels in the control group on a chow diet remained at approximately the same level throughout the 12 months of the study, whereas those on a WD (progression group) developed significantly increased plasma cholesterol levels ( Figure The mean AV cusp separation distance, a measure of AS, was within the range of 0.85 to 0.95 mm in the control mice before and throughout the study ( Figure 1A) . In sharp contrast, AV cusp distance steadily decreased in the progression group during the 12 months of the experiment, going from 0.86±0.03 to 0.31±0.03 mm (P<0.01). Reversal of hypercholesterolemia slowed the rate of reduction in AV cusp distance, such that it was 0.46±0.03 mm at 12 months (P<0.01 compared with the progression group value; Figure 1A ). Feeding Reversa mice a WD for 6 months led to AV thickening and increased AV collagen deposition, and the abnormalities were more severe after 12 months ( Figure III progression panels in the online-only Data Supplement). Reversal of hypercholesterolemia at 6 months slowed the progression of AV thickening from 6 to 12 months but had no effect on collagen deposition ( Figure III Both WSS Across the AV and Plasma Total TGF-β1 Levels Increase After 6 Months in Reversa Mice on a WD Transvalvular peak velocity and WSS on the ventricular side of the AV, which is ≈3× to 4× higher than on the aortic side under normal circumstance, 21 remained unchanged in the control group throughout the experiment ( Figure 1B and 1C) . In sharp contrast, ventricular WSS increased from 191±20 to 412±32 dyn/cm 2 after 6 months of WD in the progression group (P<0.01 versus control group at 6 months). It continued to increase during the next 6 months in the progression group, reaching a value of 1053±189 dyn/cm 2 . WSS was lower in the reversed group at the 9-month time point than in the progression group (P<0.01). Between 9 and 12 months, WSS in the reversed group increased 38% but still remained significantly lower than in the progression group (P=0.04; Figure 1B ). Plasma total TGF-β1 levels in the control group were 0.87±0.05 ng/mL at baseline and remained <1.00±0.02 ng/ mL throughout the 12 months of the experiment ( Figure 1D ). In contrast, in the progression group, the plasma total TGF-β1 increased from 1.02±0.02 ng/mL to 1.67±0.10, 1.94±0.18, and 1.79±0.11 ng/mL after 3, 6, and 9 months of WD, respectively; the value remained elevated at 1.90±0.16 ng/mL after 12 months (all P<0.01 versus baseline value and P<0.05 versus control group at 0, 3, 6, 9, and 12 months). TGF-β1 levels were lower in mice in the reversed group than in the progression group at the 9-month time point (1.11±0.05 ng/mL; P<0.001) but still higher than in the control group (P<0.05). Plasma TGF-β1 levels increased to 1.54±0.10 ng/mL at 12 months in the reversed group (39% increase from 9 months), a value significantly higher than that of the control group (P<0.001) but lower than that of the progression group (P=0.03; Figure 1D ). There was considerable variability between animals, but there was a weak correlation between the change in WSS from baseline to 6 months and the change in plasma TGF-β1 levels during the same time period in the progression group (r=0.37; P=0.03) but not in the control group (r=−0.38; P=0.08; Figure  1E ). There was a trend toward a correlation between the change in plasma total TGF-β1 from 9 months to 12 months and the change in WSS during the same period in the reversed group (r=0.50; P=0.06; Figure 1F ). The changes in plasma TGF-β1 levels from baseline to 6 months and from 9 months to 12 months did not correlate with changes in cholesterol levels in either group during the same time periods (data not shown).
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WSS Across the AV in Reversa Mice and the Stenosis Created in AAC Model
Association Among Plasma TGF-β1 Levels, AV Collagen Deposition, and Systolic Cardiac Function
The association between plasma TGF-β1 and the area of the AV staining positive for collagen, a measure of valve fibrosis, was measured at 6 and 12 months (Figure 2A and 2B). There was no association in control animals at either time point (r=0.01 and 0.24, respectively; P=0.97 and 0.45, respectively; Figure 2A and 2B, control group). In the progression group, the correlation coefficients at 6 and 12 months were 0.47 and 0.78, but the associations were not statistically significant (P=0.19, n=9 and P=0.08, n=8; Figure 2A ). The correlation in the regression group at 12 months (n=15) was statistically significant (r=0.77; P<0.01; n=15; Figure 2B ). Plasma TGF-β1 levels showed a trend toward a negative association with ejection fraction in both the reversed and progression groups at 12 months ( Figure 2D ; r=−0.50 and −0.63, respectively; P=0.06 and P=0.09, respectively) but not at 6 months ( Figure 2C for progression group versus regression group). Almost all of the calcifications were found in the ascending aorta above the AVs. The calcification was, for the most part, localized to relatively small areas, raising the possibility that they were in reaction to a jet of blood hitting the wall as it exited from the narrowed valve. There was no correlation between the extent of calcification and either the TGF-β1 level or WSS (r=0.30, P=0.47 and r=0.24, P=0.26, respectively). Figure 3A and 3B shows representative sections of AVs stained for phosphorylated Smad2/3 (p-Smad2/3), a canonical TGF-β1 pathway intermediate, and phosphorylated extracellular signal-regulated kinases 1/2 (p-Erk1/2), a noncanonical TGF-β1 pathway intermediate, respectively, in the 3 groups at different time points. The AVs stained more intensely for p-Smad2/3 in the progression group than in the control group at 6 and 12 months, and most of these p-Smad2/3-positive cells expressed vimentin, indicating that they were valvular interstitial cells (VICs) rather than endothelial cells ( Figure   3A ). There was baseline p-Erk1/2 staining in endothelial cells (identified by von Willebrand factor staining) in mice on a chow diet. The percentage of cells staining for p-Erk1/2 dramatically increased after the development of AS in the progression group at both 6 and 12 months. Most p-Erk1/2-positive cells did not express von Willebrand factor, indicating that they were VICs rather than endothelial cells ( Figure  3B ). p-Smad2/3 and p-Erk1/2 staining of the valve leaflets of mice in both the reversed and the progression groups after 12 months was more intense than in the control group (P<0.05 for both; Figure 3 ). There was no significant association between either p-Smad2/3 or p-Erk1/2 staining and collagen deposition in either the reversed or the progression group at 12 months ( Figure months despite the reduction in cholesterol levels suggested that shear-induced latent TGF-β1 release and activation may have its effect on AVs through the noncanonical TGF-β1 pathway. Because the data from the in vivo mouse studies suggested that TGF-β1 might be able to stimulate both the canonical and noncanonical pathways of TGF-β1 signaling in VICs, we tested the effect of exogenous TGF-β1 on VICs. We found that TGF-β1 transiently activated both the canonical and noncanonical pathways ( Figure 4A ). To test whether Erk1/2 phosphorylation required p-Smad2/3 signaling, we reduced Smad2 levels by ≈80% using small interfering RNA and then activated the cells with TGF-β1; Erk1/2 phosphorylation still occurred in response to TGF-β1 although there was virtually no Smad2/3 phosphorylation ( Figure 4B ), suggesting that the noncanonical pathway activation in VICs was independent of the activation of the canonical pathway. To further determine the relative contribution of the canonical and noncanonical TGF-β1 A, Immunoblot of VIC after treatment with 0.5 ng/ mL TGF-β1. B, Effect of reducing small mothers against decapentaplegic (Smad) 2 in VIC with small interfering RNA (RNAi) on TGF-β1-induced extracellular signal-regulated kinase (Erk) 1/2 phosphorylation. C, Changes in mRNA levels of fibrosis-related and calcification-related genes after knocking down Smad2 or Erk2. *P<0.05 vs control, n=3. α-SMA indicates α-smooth muscle actin; ALP, alkaline phosphatase; BMP4, bone morphogenetic protein; Col1a2, collagen, type I, alpha 2; Col3a1, collagen, type III, alpha 1; CTGF, connective tissue growth factor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MMP13, matrix metalloproteinase 13; p-Erk1/2, phosphorylated Erk1/2; p-Smad2/3, phosphorylated Smad2/3; RNAi, ribonucleic acid interference; Runx2, Runt-related transcription factor 2; and scramble, a negative control siRNA with no homology to any known mammalian gene.
Both the Canonical and Noncanonical TGF-β1 Signaling Pathways Were Activated in the AVs of Reversa Mice in Both Progression and Reversed Groups
pathways to fibrosis or calcification in VICs, Smad2 or Erk2 was knocked down separately and fibrosis-related and calcification-related gene expression levels were analyzed after 48 hours of TGF-β1 treatment. TGF-β1 treatment led to increased mRNA levels in both fibrosis-related and calcification-related genes in control cells treated with a scrambled small interfering RNA. In sharp contrast, knocking down either Smad2 or Erk2 significantly decreased the response to TGF-β1 ( Figure 4C ). These data suggest that both the canonical and noncanonical TGF-β1 pathways contribute to fibrosis and calcification.
Acute Surgical Constriction of the Ascending Aorta in WT and Tgfb1 flox Mice Leads to Increases in Plasma Total TGF-β1 Levels and WSS; the TGF-β1 Levels Correlated With WSS in WT But Not Tgfb1 flox Mice
To further assess the effect of increased WSS on TGF-β1 levels in a mouse model that simulates the hemodynamics of AS in the absence of hypercholesterolemia, we performed AAC surgery on WT mice and Tgfb1 flox mice. The experimental scheme is shown in Figure 5A . In response to surgery, WSS at the site of stenosis increased ≈20-fold 1 week after the surgery and remained elevated at 4 weeks ( Figure 5A, inset) . Baseline TGF-β1 levels of Tgfb1 flox mice were ≈30% lower (median, 0.72 ng/mL; interquartile range, 0.60-0.80 ng/mL) than those of WT mice. In WT mice, total TGF-β1 levels increased from a median of 1.02 ng/mL (interquartile range, 0.92-1.36 ng/ mL; n=23) before surgery to 1.26 ng/mL (interquartile range, 1.06-1.58 ng/mL; 24% increase) and 1.35 (interquartile range, 1.08-1.54 ng/mL; 32% increase) at 1 and 4 weeks after AAC surgery, respectively (both P=0.01; Figure 5B ). Tgfb1 flox mice had 35% to 40% lower TGF-β1 levels than WT mice at 1 week and 4 weeks after surgery (0.82 ng/mL at both 1 and 4 weeks; n=20; P<0.01 at both time points versus WT mice; Figure  5B ). WSS at the site of the stenosis correlated positively with plasma total TGF-β1 levels in WT but not Tgfb1 flox mice after AAC surgery ( Figure 5C and 5D) . The left ventricular ejection fraction decreased in both groups by ≈27% at both 1 and 4 weeks after AAC surgery (data not shown). Ejection fraction correlated negatively with the plasma total TGF-β1 levels in WT mice 1 week and 4 weeks after surgery (both P<0.01) but not in Tgfb1 flox mice (both P>0.05; Figure 5E and 5F). Plasma total TGF-β1 levels correlated positively with the left ventricular interstitial fibrosis score in the combined group of WT and Tgfb1 flox mice (r=0.48; P=0.025; n=43). Left ventricular systolic function (ejection fraction) was negatively associated with the fibrosis score in the group composed of WT and Tgfb1 flox mice (r=−0.87; P<0.001; n=43; Figure VII in the online-only Data Supplement). WT mice showed evidence of both canonical and noncanonical signaling in the ascending aorta near to where the stenosis was created, suggesting local TGF-β1 activation under high shear stress ( Figure VIII in the online-only Data Supplement). In sharp contrast, the Tgfb1 flox had much less evidence of TGF-β1 signaling, suggesting that platelet-derived TGF-β1 rather than tissue-derived TGF-β1 was the source of the active TGF-β1.
Platelet-Derived TGF-β1 Can Initiate Phosphorylation of Smad2/3 in CD45 +
Leukocytes After Stirring Whole Blood
Because plasma levels of active TGF-β1 in both Reversa mice and mice that underwent AAC surgery were too low to be detected by ELISA, we tried to develop a surrogate indicator of circulating activated TGF-β1. The first step was to check the phosphorylation of Smad2/3 in leukocytes contained in whole blood with or without stirring to increase shear. We found that stirring the blood of WT mice for 40 minutes dramatically increased the percentage of p-Smad2/3-positive leukocytes from 1.6±0.4% to 30.7±8.9% (n=6; P=0.003; Figure 6B , with a representative experiment shown in Figure 6A ). To assess the role of TGF-β1 in p-Smad2/3, we also stirred whole blood from Tgfb1 flox mice and found a much lower p-Smad2/3 response, going from 1.2±0.3% to 7.2±2.3% (n=6; P=0.08 compared with unstirred value and P<0.001 compared with value in WT mice after stirring). Similar results were obtained by immunoblotting of lysed whole blood ( Figure 6C ). To further assess whether the increase in leukocyte p-Smad2/3 in WT mice was because of active TGF-β1, we repeated the experiments in the presence of an antibody to TGF-β1 and found that the antibody attenuated the stirring-induced increase in WT leukocyte p-Smad2/3 by 44% (13.5±7.3%; n=6; P=0.03; Figure 5 . Plasma total transforming growth factor-β1 (TGF-β1) levels increase after ascending aorta constriction (AAC) surgery; the increased TGF-β1 levels correlate with wall shear stress (WSS) at the site of the stenosis in wild-type (WT) but not Tgfb1 flox mice. A, Experimental design and WSS (inset) before (pre) and 1 and 4 weeks after AAC surgery. B, Plasma total TGF-β1 levels before and 1 and 4 weeks after AAC surgery in WT and Tgfb1 flox mice (median is shown on the plot; *P<0.001 between the 2 groups). C and D, Correlations between plasma total TGF-β1 levels and WSS at the site of aortic stenosis in WT and Tgfb1 Figure 6A-6C). To assess whether platelet granule release was required for the increase in leukocyte p-Smad2/3, we also tested the effect of adding the platelet activation inhibitor prostaglandin E 1 . It also attenuated the increase in leukocyte p-Smad2/3 as shown by immunoblotting ( Figure 6C ). We concluded that platelet-derived, shear (stirring)-activated TGF-β1 was responsible for the increase in leukocyte p-Smad2/3.
Reversa Mice on a WD for 3 Months Have More p-Smad2/3 in Their CD45 + Leukocytes Than Those on Chow Diet or WT Mice on Chow Diet, Suggesting the Presence of More Circulating Active TGF-β1
Based on the ex vivo assay described above, we tested whether there was more p-Smad2/3 in the leukocytes in the blood of Reversa mice on a WD for 3 months without stirring than in the leukocytes of age-and sex-matched Reversa mice on a chow diet or WT mice. We found that 5.8±1.0% of CD45 + leukocytes were p-Smad2/3 positive in Reversa mice on a WD compared with 1.2±0.3% of leukocytes in Reversa mice on chow diet and 2.1±0.5% in WT mice (P=0.004 and P=0.01, respectively, versus Reversa mice on a WD diet; Figure 6D ). Similarly, we found higher leukocyte p-Smad2/3 mean fluorescent intensity in Reversa mice on a WD (302±23 arbitrary units [AU]) than Reversa mice on a chow diet and WT mice (236±17 AU and 244±11 AU, respectively; both P=0.04; Figure 6E ). A representative p-Smad2/3 flow cytometry histogram for 1 mouse in each group is shown in Figure 6F .
Discussion
AS, characterized by reduced AV area and increased shear stress, is estimated to affect >25% of people aged >65 years. 3 Although inflammation, oxidative damage, and osteogenesis have been reported to contribute to the pathogenesis of AS, to date there is no effective medical therapy, 6, 22 and so AV replacement, either surgically or percutaneously, is the only effective treatment. 1, 23 Based on our previous observation that high shear stress can induce release and activation of plateletderived latent TGF-β1, 11 a cytokine that can induce fibrosis and calcification in explanted AV interstitial cells, 12, 24 we hypothesized that high shear stress across a stenotic AV could both induce release of platelet TGF-β1 and activate it in the circulation, leading to progressive AV fibrosis, calcification, and further stenosis. To test this hypothesis, we used a nonsurgical model of diet-induced AS and a surgical model of AS that closely simulates the hemodynamics of severe AS.
In the hypercholesterolemic mouse model, we found that the onset of AV abnormalities occurred within 3 months after starting the WD. Plasma TGF-β1 levels also increased within 3 months in these animals and remained elevated thereafter. Although there was a weak correlation between the increase in TGF-β1 and the increase in WSS from baseline to 6 months, the TGF-β1 increase reached near-maximum levels at 3 months, a time point at which WSS was only slightly increased. Thus, it does not seem that increased WSS can completely account for the increase in plasma TGF-β1. Hypercholesterolemia may have also contributed to the increase in TGF-β1 levels by making platelets more sensitive to shear-induced activation and degranulation. 25, 26 Additionally or alternatively, hypercholesterolemia may have increased release of TGF-β1 from sources other than platelets. 27, 28 Support for a role for hypercholesterolemia comes from the data in the reversed group of Reversa mice. Their hypercholesterolemia was nearly normalized at 9 months associated with a significant reduction in plasma TGF-β1 levels. Furthermore, Zhou et al 29 reported a correlation between cholesterol and plasma TGF-β1 levels in apolipoprotein E-deficient mice placed on a high-fat diet. The increase in plasma TGF-β1 levels between 9 and 12 months in the reversed group was associated with an increase in WSS but these mice had nearly normal cholesterol levels, indicating a potential role of WSS in increasing plasma TGF-β1 levels in the absence of hypercholesterolemia. Collectively, these data suggest a complex relationship between hypercholesterolemia and WSS as factors in increased TGF-β1 levels. To further assess the impact of increased aortic WSS on TGF-β1 levels in the absence of hypercholesterolemia and assess the contribution of platelet TGF-β1 to any change in plasma TGF-β1, we surgically constricted the ascending aorta of WT mice and Tgfb1 flox mice whose platelet TGF-β1 levels are only ≈15% of those of WT mice. Plasma TGF-β1 levels increased in both WT mice and Tgfb1 flox mice but only correlated with increased WSS in WT mice but not Tgfb1 flox mice. These data further support the hypothesis that high shear stress can lead to release of platelet-derived TGF-β1.
Although we could not detect active TGF-β1 in plasma of Reversa mice, probably because the current assays are not sensitive enough to detect the picomolar levels expected based on total TGF-β1 levels, the relatively low percentage of total TGF-β1 that becomes activated by shear, 11, 30 and the reported short survival of active TGF-β1 in the circulation, 31, 32 we found activation of both canonical (p-Smad2/3) and noncanonical (p-Erk1/2) pathways in VICs of the stenotic AVs, indicating the possibility of local TGF-β1 activation under high shear stress. We also found evidence of both canonical and noncanonical TGF-β1 signaling in the local area of high shear in the ascending aorta of WT mice in the AAC model. There was much less TGF-β1 signaling in the Tgfb1 flox mice, suggesting that plateletderived TGF-β1 is the likely source of the active TGF-β1. In vitro studies of cultured human AV interstitial cells with exogenous TGF-β1supported these in vivo findings and indicated that activation of the noncanonical pathway is independent of the activation of the canonical pathway on VICs. These data are in accordance with previous studies indicating that TGF-β1 independently activates both the canonical and the noncanonical pathways. 12 The identification of a potential role of the noncanonical pathway in AS in this model is of interest because Erk1/2 is important in epithelial mesenchymal transition, 33 regulating cell proliferation and apoptosis 34 and calcification of VICs. 35 We found that increased Smad and Erk signaling persisted in the regression group at 12 months despite the reduction in cholesterol and the partial reduction in plasma TGF-β1 levels, raising the possibility that even a modest elevation in plasma TGF-β1 may be sufficient to induce signaling.
Because active TGF-β1 could not be directly detected in the plasma of mice, we developed an indicator of platelet-derived circulating active TGF-β1 based on our in vitro findings that stirring mouse whole blood produced an increased p-Smad2/3 in leukocytes. Support for the increase in p-Smad2/3 being because of stimulation by TGF-β1 came from data showing that an antibody to TGF-β1 inhibited the Smad2/3 phosphorylation, as did the platelet granule release inhibitor prostaglandin E 1 . Further support for the platelet origin of the TGF-β1 in these studies came from parallel studies using Tgfb1 flox mice because the p-Smad2/3 signal was dramatically reduced with the blood from these animals. By using this assay, we found a significant increase in leukocyte p-Smad2/3 in the Reversa mice on the WD but not on the chow diet. Thus, although it has been postulated that shear force may activate TGF-β1 in a paracrine fashion through valve tissue stretching and mechanical, traction-based cellular activation, 4 our results suggest that additionally or alternatively shear force may lead to activation of circulating TGF-β1.
In summary, our in vivo data provide direct or indirect evidence for (1) a complex relationship between hypercholesterolemia and shear in increasing plasma TGF-β1 levels in a diet-induced mouse model of AS; (2) a role for TGF-β1 signaling through both its canonical and noncanonical pathways in the AV abnormalities in this model; and (3) the presence of active TGF-β1 in the circulation in this model.
Complementary in vitro data demonstrate that shear stress can release TGF-β1 from platelets and activate it to levels that can induce a biological response in leukocytes. These data raise the possibility that interfering with TGF-β1 activation or its effects on the canonical and noncanonical pathways may slow the progression of AS. It will, however, require direct demonstration that preventing TGF-β1 release or activation, or neutralizing its activity, prevents pathological AV changes to establish a causal relationship.
